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ABSTRACT Periorificial dermatitis, mostly known as perioral dermatitis, 
is a benign inflammatory facial dermatosis which can be a severe bur-
den and even disfiguring and psychologically disturbing. The disease 
still presents a challenge for physicians when it comes to etiology and 
appropriate therapy. Although a variety of extrinsic and intrinsic factors 
have been proposed as etiopathogenetic factors, none of these fully ex-
plain complex pathogenesis of the disease. There is more evidence that 
supports beliefs that the epidermal barrier dysfunction is an underlying 
main pathogenic factor that contributes to persistent cutaneous inflam-
mation in typical facial localizations. Patients with periorificial dermatitis 
are considered hyper-reactors who have impaired essential function of 
the skin barrier, especially the skin barrier of the perioral region, char-
acterized by thin permeable stratum corneum and imbalance of inter-
cellular lipids, which makes them more susceptible to various internal 
and external irritants that contribute to the development of the disease. 
The verification of this connection reinforces the need for clinicians to 
address this issue when approaching their patients and formulating 
the best treatment plan. Treatment should emphasize repairing the im-
paired skin barrier function to minimize associated skin inflammation 
and sensitivity, which results in resolution of the objective and subjec-
tive symptoms. 
KEY WORDS: skin barrier, periorificial dermatitis, perioral dermatitis, 
transepidermal water loss, corticosteroids
INTRODUCTION
Periorificial dermatitis (PD) is a benign inflamma-
tory facial dermatosis presenting in both children 
and adults as persistent grouped tiny erythematous 
papules, papulovesicles, and papulopustules some-
times on the background of pink, scaly patches (1,2). 
Although its most common form is perioral with char-
acteristic spared skin zone around the vermilion bor-
der, there can be additional or exclusive periocular 
and perinasal involvement, which is the reason why 
the term periorificial dermatitis is used (3). Patients 
frequently complain of subjective symptoms like 
burning or stinging and/or pruritus. The disease is in-
creasing in its incidence but still presents a challenge 
for physicians when it comes to etiology, patho-
physiology, and appropriate therapy. Several etio-
pathogenetic factors have been proposed, but none 
of these fully explains the intricate pathogenesis of 
the disease (4-7). In addition to the most well-known 
contributing factor, topical corticosteroids (TC) (8), 
several other factors have been proposed including 
excessive skin cleaning and washing, occlusive skin 
moisturizers, physical sunscreens and cosmetic prod-
ucts, fluoridated toothpastes, fusobacteria, Candida 
albicans, Demodex folliculorum, and hormonal influ-
ences dependent on the menstrual cycle or oral con-
traceptive therapy (1,9-13). 
169ACTA DERMATOVENEROLOGICA CROATICA
170 ACTA DERMATOVENEROLOGICA CROATICA
It is currently believed that the interplay of both 
intrinsic and extrinsic factors is crucial for the devel-
opment of PD, with an emphasis on the interaction of 
external irritants, atopic diathesis, and deficient skin 
barrier (SB) function (1,9,14,15). Deficiencies in SB 
function and features of atopy have been detected at 
increased frequency in patients with PD (14-16), so it 
is believed that impaired SB function could augment 
the risk of persistent cutaneous inflammation after 
exposure to external and internal irritants, but its de-
finitive role has not been established yet.
In order to corroborate the previously proposed 
role of SB in PD, we conducted a clinical review on 
the state of the SB in PD and its proposed role in the 
etiopathogenesis of the disease as well as the fac-
tors influencing SB function which result in occur-
rence or worsening of PD. Four databases, EMBASE, 
SCOPUS, MEDLINE (PubMed), and Google Scholar 
were thoroughly searched using the following key 
terms: “periorificial dermatitis”, “perioral dermatitis”, 
“periocular dermatitis’’, “skin barrier”, and “corticoste-
roids”. The selection process was performed through 
an initial screening of titles and abstracts, followed by 
evaluation of full-text articles. Further papers were 
also identified from the reference lists of the above-
retrieved papers and citations, as identified by Web 
of Science.
The function of skin barrier defects in 
most common inflammatory facial skin 
disorders – atopic dermatitis and rosacea
The skin is both a physical, “chemical”, and im-
munological antimicrobial barrier that has a critical 
role in the prevention of water loss, preservation of 
electrolyte balance, allergen penetration, and host 
defense against microbial invasion (17). The main 
component of the SB is the multilayered stratum cor-
neum (SC), often modeled as a brick wall because of 
its filmogenic features due to SC corneocytes with 
their resistant cell envelopes and keratin microfibrils 
that produce a physical barrier of a cross-linked ma-
trix containing various proteins and multiple lamel-
lar sheets enriched in ceramides, cholesterol and free 
fatty acid (18,19). Nucleated cells with a cytoskeleton 
and tight and gap junctions contribute to the physi-
cal barrier. Filaggrin (FLG) and proteins of the tight 
junctions (TJs) (occludin, claudin, zonula occludens 
1 and 2, junctional adhesion molecule-1, and multi-
PDZ-1) have been the most studied components of 
the SB (20-23). FLG, after being hydrolyzed, contrib-
utes to the formation of relevant components for pH 
maintenance, moisture, and skin protection against 
microbial agents (24-26). TJ proteins with active 
expression, on the other hand, are important to con-
trol the selective permeability of the epidermis to form 
the barrier against the external influences (20,27,28). 
The “chemical” barrier is formed by lipids, the “acid 
mantle”, antimicrobial peptides (AMPs) secreted by 
keratinocytes, mast cells (MCs) and sebocytes, and the 
FLG that aggregates keratin filaments and produces 
natural moisturizing factors (NMF) (19,29). These com-
ponents synergistically ensure proper keratinization 
and lipid synthesis, providing antimicrobial protec-
tion and adequate skin hydration. 
An intact SB can be regarded as the first and most 
essential component of the innate immune system 
(17). It is well-known from various studies, mostly ex-
amining atopic dermatitis (AD), that the impairment 
of the SB function, which corresponds to increased 
transepidermal water loss (TEWL) (30) and decreased 
SC hydration, is correlated to initiation of a cytokine 
cascade in the human skin (24,29,31,32), which sup-
ports the claim that dysfunction of SB greatly contrib-
utes to triggering and perpetuation of inflammation 
in the affected skin. Patients with AD and deficiency 
in FLG expression have decreased SC hydration, in-
creased TEWL, higher pH which causes impaired 
serine protease activation and modification of micro-
biome, impaired skin integrity due to reduced pro-
tein expression in keratinocytes, and impaired AMPs 
function which leads to ongoing inflammation that 
contributes to already impaired SB function (29,33). 
It is not only in AD, but also other inflammatory der-
matoses such as rosacea, that increased basal TEWL 
activates certain epidermal proteases, specifically SC 
serine proteases, and this activation leads to inflam-
mation (15,16,34-36).
Not all patients with AD can attribute their disease 
to FLG mutations; in such patients we can detect oth-
er causes of the impaired barrier, mostly altered com-
position and structure of the lipids (37-42). Skin lipids 
produced by sebaceous glands not only contribute 
to integrity, but also exhibit strong antimicrobial ac-
tivity (43). In addition to the FLG mutations and lipid 
disbalance, there are numerous factors which can 
be influenced and whose functions can be altered, 
since many proteolytic enzymes and protease inhibi-
tors are involved in obtaining the normal function 
and structure of the barrier. We can say that all the 
important functions of the barrier are a result of the 
barrier’s structure and organization. Except for genet-
ic predisposition, where FLG mutation has the central 
role, many exogenous and endogenous stressors can 
additionally compromise SB, such as psychosocio-
logical stress, environmental pollution, and hygiene 
products/cosmetics which cause further damage to 
the SB (29,35,44-47). 
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In rosacea, as one of the most common facial 
dermatoses that is being clinically correlated to PD 
according to some authors, studies assessing SB are 
scarce and they focus mostly on sebum production 
(48). Two studies reported that rosacea depends more 
on skin hydration levels, with dry skin being affected 
the most, than on the amount of sebum (49,50). Sur-
prisingly, there is data that supports evidence that se-
bum production is important but due to the content 
itself, particularly of fatty acids, which may influence 
the SB integrity of patients with rosacea (51). 
Rosacea has a complex pathophysiology char-
acterized by a modified innate immune response to 
environmental stimuli (52,53). Under normal physi-
ologic conditions, triggering the innate immune sys-
tem leads to controlled increases in AMPs (e.g. cat-
helicidins, defensins, psoriasins) and cytokines in the 
skin (54,55). These pathways are disrupted in patients 
with rosacea who have been shown to have increased 
baseline expression of AMP cathelicidin and serine 
protease kallikrein 5 (KLK5) that cleaves cathelicidin 
into its active peptide form – cathelicidin LL-37 (Cath 
LL-37), which possesses proinflammatory and angio-
genic properties by promoting leukocyte chemotaxis 
and angiogenesis (56-59). Although mostly attribut-
ed to the pathophysiology of rosacea, Cath LL-37 is, 
along with other overexpressed AMPs, also implicat-
ed in the pathogenesis of AD and psoriasis (55,60,61). 
Not only is KLK5 increased in rosacea pathology, but 
there is also an increase in molecules that activate 
it and promote inflammation, i.e. Toll-like receptor 
2 (TLR2) and matrix metalloproteinases (MMPs) (62-
64). Zheng et al. (65) showed that Cath LL-37 also 
stimulates the generation of reactive oxygen species 
(ROS); their importance in rosacea pathophysiology 
is emphasized by the effectiveness of the most com-
monly used topical agent in the treatment of rosacea 
and PD – metronidazole (66). Cath LL-37 has emerged 
as a key mediator in the pathogenesis of rosacea af-
ter being examined in animal studies, which showed 
that intradermal administration of Cath LL-37 induces 
an inflammatory response with rosacea-like features 
(56). Doxycycline, which is a proven and effective 
treatment for both rosacea and PD, directly inhibits 
MMP-9 which in turn inhibits KLK5 activity, suppress-
es activation of cathelicidins in human epidermal ke-
ratinocytes, and results in suppression of inflamma-
tion and clinical improvement (67,68).  
MCs which are well-known as one of the cells re-
sponsible for secretion of AMPs, have recently been 
identified as key mediators of cathelicidin-initiated 
skin inflammation in rosacea (69-71). MCs, MC prote-
ases, and MMP-9 are found in increased numbers in 
the skin of patients with rosacea. It is known that this 
cell type partly regulates SB function, not only by be-
ing the primary source of Cath LL-37 responsible for 
the inflammation and worsening of the SB but also 
by acting through its proteases responsible for vaso-
dilatation and angiogenesis as well as amplification 
of the inflammation by recruitment of other immune 
cells, primarily neutrophils (69,72). The most abun-
dant MCs mediator is tryptase, which causes direct 
proteolytic damage, activates proteinase-activated 
receptors and neuropeptides precursors, and causes 
inflammation. MCs are rich in proinflammatory me-
diators, particularly tumor necrosis factor and IL-6, 
which could also perpetuate local inflammatory pro-
cesses in response to chemical, mechanical, psycho-
logical, or oxidative stress (72).
The impairment of the skin barrier in peri-
orificial dermatitis 
As mentioned previously, current understand-
ing of the etiopathogenesis of the PD points to the 
importance of skin-environmental interactions with 
an emphasis on the interaction of external irritants, 
atopic diathesis, and impairment of SB function (73). 
The clinical observation of a tight association of PD 
with sensitive skin has led scientists to the concept 
of abnormal epidermal barrier function in PD that is 
in contrast to AD restricted only to facial skin, with 
both clinically involved and uninvolved areas of the 
facial skin having SB impairment, mostly the perioral 
region, suggesting the presence of mild invisible 
inflammation (15,74). A Japanese group of authors 
conducted a study to evaluate differences in bio-
physical functions of skin in distinct facial regions 
(74). They showed that the barrier function of SC is 
significantly poorest on the chin, whereas the naso-
labial fold region presented with the highest TEWL, 
in contrast to the cheek region presenting with the 
lowest TEWL. Furthermore, the corneocytes on the 
chin and the nasolabial folds were smaller than those 
on the cheeks but increased in size with age, which 
is in concordance with results showing a decrease in 
TEWL. The group also tried to characterize the skin 
surface lipids on facial specific sites. They revealed 
that skin surface lipids were richest on the nose, fore-
head, and chin, significantly higher than those mea-
sured on the cheek, but they did not find a correla-
tion between skin surface lipids and TEWL that would 
corroborate the evidence of reduced lipids in PD skin. 
Their results are similar those of Shiner and Maibach, 
demonstrating that the nasolabial skin is the most 
sensitive area of the face when exposed to certain 
irritants (75). It is therefore understandable that pa-
tients with impaired facial SB are hyper-reactors be-
cause of the thin permeable SC which makes them 
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more susceptible to chemical irritations, namely that 
of the perioral region, leading to the development of 
PD (76,77). Although patients with impaired facial SB 
are considered to be hyper-reactors, and the impor-
tant feature of many “hyper-reactive” skin diseases is 
mounting of excessive immune cell response to low-
level stimuli (78), there are still no studies focusing 
on the immune dysfunction in PD, either in the skin 
or systemically. Skin of rosacea-prone persons and 
patients presenting with sensitive skin both have in 
common perpetuation of perivascular, epidermal, 
and dermal inflammation which synergistically accel-
erates epidermal proliferation and differentiation, re-
sulting in functionally impaired SC without the ability 
to maintain proper hydration. This leads to hydration 
loss and increased TEWL, which is already increased 
by the underlying inflammation. As explained previ-
ously, similarly as in AD, in addition to increased TEWL 
certain epidermal proteases are being activated and 
there is a change in the innate immune functions, in-
cluding an increase in AMPs that leads to ongoing in-
flammation. It is possible that dysregulation of the in-
nate immune system, very similar to the one involved 
in rosacea and AD, is the core pathogenetic pathway 
that augments the risk for persistent skin inflamma-
tion in patients with PD who already have impaired 
SB and features of atopy and who are exposed to ex-
ternal stressors/irritants. 
Since skin lipids are crucial for a healthy skin bar-
rier (38,79), we tried to find articles presenting direct 
evidence of reduced lipids in PD skin, but there were 
no studies that examined at least one component 
crucial for SB function in this group of patients. Para-
doxically, there were studies showing that excessive 
use of moisturizers, especially occlusive moisturizing 
emollients based on paraffin or petrolatum jelly, can 
be irritating for the facial skin and result in SB dysfunc-
tion, leading to edema of the SC and increased TEWL, 
leading to the conclusion that the skin lipids content 
and the structure is more important than the quantity 
itself (9,15). An Australian study conducted by Malik 
corroborated the role of excessive topical cosmetics 
usage in the development of PD by demonstrating 
that a combination of moisturizer, night cream, and 
foundation significantly increases the risk of PD (80). 
Dirschka et al. (14) investigated facial SB function and 
various markers of atopy to elucidate their role in the 
development of PD. On the basis of their findings, 
they proposed that atopy serves as an intensifier that 
contributes to ongoing inflammation in PD after non-
specific irritants have induced impaired SB function. 
Unfortunately, despite some minor investigative and 
clinical studies, there are currently no studies or evi-
dence that would corroborate the role of SB function 
in PD pathogenesis by elucidating specific molecular 
or genetic pathways. Established link between SB 
dysfunction and the cutaneous cytokine cascade ex-
plained in detail in AD pathogenesis (29,32) has not 
been studied in PD, although deficiencies in SB func-
tion and features of atopy have been detected in the 
majority of patients with PD. 
Topical steroids – skin barrier – periorifi-
cial dermatitis
It is well-known that TC use triggers or aggravates 
PD, and therefore it should be avoided as much as 
possible when dealing with this group of patients. It 
is not only TC usage, but also the use of inhaled or 
nasal corticosteroids, and even the “connubial” expo-
sure from intimate contact with another person who 
uses TC that can result in the disease (12). 
Since their first introduction in 1951, the abuse of 
the TC has been a prevalent problem. Although it is 
strongly suggested to avoid prolonged continuous 
and/or repeated intermittent TC use in disorders like 
PD and rosacea, these instructions are often not ad-
hered to by the patients (81). Initial improvement of 
their symptoms with TC treatment leads to prolonged 
misuse and long-term dependency on TC that result in 
adverse effects such as epidermal atrophy, degenera-
tion of dermal structure, and collagen deterioration 
that are predictable but difficult to manage (82,83). 
Both human and animal model studies showed vari-
ous cutaneous abnormalities that occurred as a result 
of TC use, including alterations in epidermal struc-
ture and SB permeability that lead to increased TEWL 
(8,37,84). When we translate these findings into clini-
cal practice, we often see that the routine misuse of 
fluorinated TC on the face results in an large group of 
skin complications like PD and an eruption clinically 
indistinguishable from rosacea – “steroid-induced ro-
sacea” – which is also known in literature under the 
term corticosteroid-induced rosacea-like dermatitis 
(CIRD) (34,82). CIRD was reported by Del Rosso to 
occur more commonly in female patients (72%), of-
ten with a history of atopy (67%), and the patients 
additionally reported symptoms such as burning, 
stinging, dryness, and pruritus (34). It is believed that 
anyone may develop this complication; however, 
it may be that rosacea-prone persons and persons 
with sensitive skin or history of atopy are more sus-
ceptible, which could be explained by the fact that 
both the facial skin of these group of patients and 
those who had been treated with TC have essentially 
impaired epidermal barrier (15,85). In patients prone 
to rosacea, with chronic TC use PD may eventually 
progress into a more severe granulomatous subtype 
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of the disease occurring in the same distribution as 
flesh-colored to erythematous or yellow-brown pap-
ules (5,86,87). It is believed that TC cause damage of 
the hair follicle wall followed by edema in the follicle 
cells, which results in the development of granulo-
matous PD (62,87). When examining the medical his-
tory of most patients in our clinical practice, we often 
came across prolonged continuous and/or repeated 
intermittent TC use. Initially, inflammation was sup-
pressed with TC, but the eruption recurred upon the 
withdrawal of the TC. According to medical history, 
most of our patients with PD that were mistreated 
with TC over a longer period had atopic dermatitis, 
seborrheic dermatitis, and sometimes rosacea (1). As 
it is usually observed in patients with PD and CIRD, 
we noticed extreme sensitivity of our patients’ facial 
skin resulting from perturbed epidermal permeabil-
ity, caused by both underlying disease, excessive skin 
cleaning, and prolonged TC use.
Stress – skin barrier – periorificial dermatitis
Stress is a term which has become ubiquitous in 
the everyday life of each and every one of us and 
presents a burden to our normal functioning. Psycho-
logical stress is triggered by a stimulus that induces 
a reaction in the brain which consequently activates 
additional physiological systems in the body, includ-
ing the nervous, endocrine, and immune system 
(88,89). There is more and more evidence and studies 
corroborating the concept of neuro-endocrine skin 
that was formulated twenty years ago, which sees the 
skin as a bi-directional platform for signal exchange 
with other peripheral organs, such as the endocrine 
and immune system (88,90,91). On the other hand, 
the skin allows the brain to achieve rapid and selec-
tive responses to the environment in order to main-
tain local and systemic homeostasis. The skin repre-
sents the first line of defense against many external 
irritants and noxic inputs, being especially sensitive 
to psychological stress according to many investiga-
tors. Studies have demonstrated that psychological 
stress alters the homeostasis of the cutaneous barrier 
as well as the adaptive immune system, which is even 
clearer in studies showing reduced recovery time of 
the SC after elimination of psychological stress (92-
95). Choi et al. (94) investigated the influence of psy-
chologic stress on SB homeostasis and showed that, 
similarly to glucocorticoids, it alters SB homeostasis 
and SC integrity and inhibits epidermal lipid synthe-
sis, resulting in decreased production and secretion 
of lamellar bodies and impaired production of lamel-
lar membranes in SC interstices. They also found that 
topical treatment with physiologic lipids restores 
both permeability barrier homeostasis and SC integ-
rity even in situations of ongoing psychologic stress, 
which means that topical treatment with lipids could 
be beneficial in stress-induced, barrier-associated 
dermatoses. 
Antigen presentation by epidermal Langerhans 
cells has also been altered under the influence of 
stress (96). It is therefore not surprising that many 
dermatological diseases are triggered or exacerbat-
ed by psychological stress. Stress signals initiate the 
hypothalamus-pituitary-adrenal (HPA) axis and the 
sympathetic nervous system, induce secretion of dif-
ferent neurotransmitters, cytokines, and hormones 
that possess skin receptors, and can aggravate skin 
diseases like acne, psoriasis, atopic dermatitis, rosa-
cea, and even PD (45,97-99). The exact mechanisms 
of stress-induced triggering or aggravation of PD 
have not yet been clarified. We hypothesize that 
glucocorticoids and adrenal androgens which are 
released during emotionally stressful periods lead to 
skin hyper-sensitivity to various other stimuli but also 
provoke or sustain inflammation through activation 
of an impaired epidermal barrier-initiated cytokine 
cascade and AMPs disbalance. The influence of psy-
chological stress on SB function, just as the influence 
of endogenous glucocorticoids, could be connected 
to the inhibition of epidermal lipid synthesis resulting 
in decreased production of epidermal lamellar bod-
ies. Because one of the functions of human epidermal 
lamellar bodies is to deliver endogenous lipids, AMPs, 
and desquamatory enzymes to SC interstices, a de-
crease in its formation contributes to an impairment 
of the antimicrobial SB function which explains the 
uncontrolled inflammatory response when such skin 
is exposed to various external irritants, especially in-
fectious agents (93,100). Based on results in the field 
of neuroimmunology showing that MCs are highly 
sensitive to modulation of stress hormones such as 
corticotropin-releasing hormone (CRH) and ACTH, 
there is increasing evidence that MCs have a func-
tional role as “switchboards” of neurogenic inflamma-
tion during stress responses (72,91). 
MANAGEMENT 
The diagnosis of PD is established clinically based 
on physical examination and clinical history. Although 
the diagnosis is straightforward in most cases, some-
times a biopsy is helpful to exclude other differential 
diagnoses like sarcoidosis, granulomatous rosacea, 
allergic contact dermatitis, or a variety of cutaneous 
adnexal neoplasms (101). Because of the perturbed 
SB of the affected facial skin, it is suggested to per-
form a “null therapy” or ‘’zero therapy’’ approach for 
the first few weeks of treatment as a way to prime the 
skin (34,102). During this period, all topical products 
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should be discontinued, including topical medica-
tions, cosmetics, soaps, astringents, abrasives, and 
occlusive moisturizers. If the history is positive for TC 
misuse, the most important step in the treatment is 
to immediately cease their application either abrupt-
ly or by tapering them down by using a low potency 
TC such as 1% hydrocortisone, or by slowly tapering 
the frequency of more potent TC application prior to 
their cessation (12,73). After subsequently priming 
the skin, usually just with saline or chamomile tea 
dressings along with a non-occlusive moisturizing 
emulsion, other beneficial therapeutic options which 
result in excellent therapeutic response should be in-
troduced. Several topical options have been suggest-
ed as first-line pharmacologic agents for PD – met-
ronidazole 0,75% gel or 1% cream, 2% erythromycin 
gel, clindamycin gel or lotion, topical sulfur prepara-
tions, azelaic acid, and calcineurin inhibitors, mostly 
1% pimecrolimus cream, especially when it comes to 
treatment of CIRD or PD induced or exaggerated by 
TC (5,34,73,103,104). However, some patients, mostly 
those with TC-induced PD, complain of irritation after 
starting topical medication, in which case the period 
of “null therapy” should be prolonged. In our clinical 
practice, we have had excellent results by applying 
this approach, which is seen in the example of a typi-
cal patient with PD presenting with a periocular vari-
ant of PD (Figure 1, a, b). 
In cases of extensive presentation of PD or if topi-
cal therapy is not enough or not helpful (we usually 
wait up to one month of application twice a day) 
systemic treatment with oral antibiotics is suggest-
ed (5). The most commonly used antibiotics for PD 
are tetracyclines because of their anti-inflammatory 
properties, but oral erythromycin is used as an alter-
native for patients who cannot tolerate tetracyclines 
or for children under age of nine due to the risk of 
adverse effects (1,73). When both topical therapy and 
oral antibiotics fail to yield the desired result, low-
dose isotretinoin can be used with good response 
(105,106). There is more and more evidence of ben-
eficial and well-tolerated treatment of PD with either 
oral or 1% topical ivermectin in individual cases, but 
well-designed prospective studies with larger num-
ber of patients are needed to corroborate its thera-
peutic role in PD (107). 
Most of our patients confirm that PD has a strong 
negative impact on their quality of life through stig-
matizing feelings and anxiety. They report that their 
facial skin condition negatively influences their emo-
tional health, which results in psychological comor-
bidities such as anxiety disorders and social phobias. 
There is no doubt that this emotional stress aggra-
vates the underlying disease even more. Therefore, 
management and therapeutic approach of PD should 
be adjusted individually, with special attention to 
triggering factors, the irritant potential of topical 
therapeutics, patient education in the disease course, 
and continuous psychological support, which results 
in improved quality of life and better social function-
ing of our patients. 
CONCLUSION
As intact SB is synonymous for healthy skin, it is 
not surprising that SB function has often been exam-
ined many times when studying various inflamma-
tory dermatoses. Although some parts of the puzzle 
are still missing, there is more clinical and observa-
tional evidence that even PD can be triggered or ex-
acerbated through disruption of SB permeability and 
function. There is also more evidence that patients 
with PD are hyper-reactors with impaired essential SB 
function, especially SB of the perioral region, charac-
terized by thin permeable SC and imbalance of inter-
cellular lipids which makes them more susceptible to 
various internal and external irritants and leading to 
the development of PD. Unfortunately, there are still 
no scientific studies which would further explain the 
Figure 1. Periocular presentation of periorificial dermatitis 
in a 45-year-old female patient. (a) Topical corticosteroid-
induced worsening of periocular dermatitis presenting as 
clustered monomorphous erythematous papules along 
with stinging sensation; (b) Marked initial improvement 
noted at two weeks after cessation of topical corticoste-
roids, treatment with a ceramide-based gentle cleanser, 
wet saline dressings, a non-occlusive moisturizing emul-
sion, and 1% metronidazole cream applied once daily. 
Balić et al. Acta Dermatovenerol Croat
Role of the skin barrier in periorificial dermatitis      2019;27(3):169-179
175ACTA DERMATOVENEROLOGICA CROATICA
exact intrinsic factors that cause changes in the SB in 
patients with PD or the specific genetic and molecu-
lar pathways responsible for the inflammation of spe-
cific facial localizations in affected individuals. More 
research in this area would corroborate the role of SB 
dysfunction in PD and be useful in improving our un-
derstanding of the development of the disease. The 
validation of SB impairment in patients with PD re-
inforces the need for clinicians to address this issue 
when approaching patients with PD and formulat-
ing the best treatment plan. The treatment should 
emphasize repair of the impaired SB function and 
reduction of the increased TEWL in order to minimize 
associated skin inflammation and sensitivity. Treat-
ment recommendations should be evidence-based, 
and the use of barrier-improving moisturizers should 
be encouraged because they shorten the treatment 
period needed for improvement and provide both 
sparing of other therapeutic agents and skin care 
maintenance quality.
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